LID/ΔM2-2/1030s

· National Institute of Allergy and Infectious Diseases (NIAID)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LID/ΔM2-2/1030s, covering 2025-08-22 to 2025-08-22. Get the full timeline:

Most recent: Clinical Trial Update: Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age [Phase 1]

See pricing